We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 126.50 | 123.00 | 130.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2021 to May 2024
By Jaime Llinares Taboada
Shares in RUA Life Sciences PLC rose Tuesday after it said that order intake for U.S. supply has returned to pre-coronavirus levels and that its vascular grafts business remains on track for FDA approval in the first quarter of 2022.
The medical-devices group said indications from its major U.S. supply customer suggest it is anticipating high-single-digit volume growth over the coming year, and opportunities are being considered regarding expanding the range of products supplied by RUA.
As for its vascular grafts division, the company said that it has already solved the contamination issues identified in previous testing. "The plan remains to have the scale up equipment fully validated during the second quarter of 2022 thus allowing us to meet growing demand for the grafts," RUA said.
Shares at 0810 GMT were up 10% at 140 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
August 31, 2021 04:33 ET (08:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Aortech Chart |
1 Month Aortech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
